sequelae.' 2 Nowhere is this problem more apparent than in the management of paediatric cancer. With almost 60% of children who have been treated for cancer in the past decade achieving long term survival and probable cure, it is becoming increasingly clear that a variety of problems are being created as a direct consequence of curative treatment. Many paediatric subspecialists other than oncologists, such as endocrinologists, cardiologists, respirologists, and neurologists are involved in the joint long term follow up of these children into adulthood. The problem of avoiding mutilating surgery has largely been achieved by the use of preoperative chemotherapy. Similarly, extended field high dose radiotherapy is now rarely used in paediatric practice. These improvements that avoid late sequelae are, however, dependent on the effective use of chemotherapy to achieve maximum response and reduce or obviate the need for further treatment directed towards local tumour control.
In an attempt to reduce chemotherapy related late sequelae there is at present considerable debate concerning which drugs could be dropped or replaced by less toxic agents. Virtually all chemotherapeutic agents are non-specific cell poisons; their effectiveness often depending on a narrow therapeutic ratio (that is, tumour cell kill to normal tissue toxicity). Up until recently the classic 'bogymen' of chemotherapy were the alkylating agents. The use of regimens such as mustine, vincristine, procarbazine, prednisolone (MOPP) or chlorambucil, vincristine, procarbazine, prednisolone (ChlVPP) 13 In solid tumours such as rhabdomyosarcoma and Wilms' tumour a series of prospective randomised studies have evaluated the need to include cyclophosphamide. The American Intergroup Rhabdomyosarcoma Study group has demonstrated clearly that this drug is not necessary to cure patients with completely resected rhabdomyosarcoma or in those with microscopic residual disease provided they are irradiated.'4 15 In the case of Wilms' tumour, cyclophosphamide is not required but with more extensive tumour the omission of this agent must be off set by the retention of an anthracycline; this is a debatable compromise. 16 In non-Hodgkin's lymphoma the overall cure rates now exceeds 80% and the necessity for including cyclophosphamide is currently being evaluated by the UKCCSG. In the UKCCSG 9001 regimen children with localised (Murphy stage 1 and 2) disease receive a non-alkylating agent regimen that does include an anthracycline. The French paediatric oncology group has reduced the duration of chemotherapy to two courses of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) for patients with stage 1 and 2 disease in the hope that the total dose of alkylating agent and anthracycline will be sufficiently low to avoid late effects. The American CCSG has opted to omit the anthracycline using the cyclophosphamide based cyclophosphamide, vincristine, methotrexate, prednisolone (COMP) regimen. Which of these options is preferable will only become apparent with further follow up in each study when information regarding sterility and cardiotoxicity is available. Attempts to avoid the alkylating agents in Hodgkin's disease include the ABVD and vincristine, etoposide, epirubicin, and prednisolone regimen. ABVD has the disadvantage of potential lung toxicity from bleomycin and doxorubicin 9ardiotoxicity. In VEEP chlorambucil and procarbazine are replaced by etoposide and epirubicin, which are nonsterilising, and it was hoped that the late cardiotoxicity of epirubicin would be less than with doxorubicin.'7 The ABVD regimen has been shown in both adults and children to be equally effective to MOPP or ChIVPP. With VEEP, however, although response rates in adults have been comparable with that seen with the ChIVPP regimen, this has not been the case in a pilot childhood study where the incidence of initial refractory disease has been worrying.'7 The strategy of using an etoposide based regimen relies on a high salvage rate, in the event of failure, using ChlVPP and radiotherapy. In this way even if there is a higher relapse rate using the VEEP regimen the overall cure rate should be comparable but the majority of boys will not be sterilised and it is hoped that second tumours will be fewer. This approach remains controversial as it involves potentially suboptimal treatment in order to avoid sterility, which should be effective in most, but accepts that the minority who relapse will end up having even more intensive treatment to achieve cure. This therefore raises the issue of how important is fertility?
Recent evidence on late effects of anthracyclines is one of the most worrying aspects of paediatric chemotherapy. ' In patients with acute lymphoblastic leukaemia there was no increased risk for children given etoposide on an alternate weekly basis, and where the drug is given once every three weeks as in most solid tumour regimens it is likely to be safe. There is, however, evidence that the more frequent scheduling of this agent may be more effective.25 26 It is probably wise to limit such regimens to those with high risk disease or after relapse where improved efficacy could outbalance the small but significant risk of transforming mutations in normal myeloid progenitor cells.
In conclusion, it is clear that we cannot expect effective curative chemotherapy to be devoid of all late sequelae. There are, however, children with tumours where at present the cure rate exceeds 70%, for example, acute lymphoblastic leukaemia, Wilms' tumour, malignant germ cell tumours, non-Hodgkin's lymphoma, Hodgkin's disease, and localised soft tissue sarcomas. For these patients protocol design will rest upon whether one accepts infertility rather than the risk of late cardiomyopathy or if soft tissue and bone hypoplasia due to localised radiotherapy is preferable to a small risk of chemotherapy related second leukaemias. This is a topic of intense debate among paediatric oncologists and many of the points raised require clarification. Because of the comparatively small number of patients involved and the high cure rates seen, prospective randomised studies evaluating the effect of omitting potentially toxic agents or the alternative late effects of newer drugs need to be done on a large multicentre, probably international, basis. The International Society for Paediatric Oncology, SIOP, is one forum where this could be done and should be encouraged to start in the near future. Empirical changes without adequate prospective evaluation may lead to replacing one toxicity by another unexpected one-out of the frying pan, into the fire. . So these data suggest that either there is no pathological dyslexia or its prevalence is less than it has been thought to be. Dyslexia due to a specific defect of neuroanatomy or neurophysiology might be expected to be fairly constant but in this study there was considerable variation with time. Defining dyslexia as a reading score more than 1-5 SDs below that expected for intelligence there was considerable movement from year to year in and out of the dyslexic group. Thus, of children defined as dyslexic in the first school year only 28% were still so defined in the third year and of those dyslexic in the third year 47% were still dyslexic in the fifth year. Equally, some children not dyslexic in the earlier school year became so later. A considerable number of children had reading scores well in advance of their intelligence. Were they superlexic? Clearly, if reading ability for IQ is normally distributed then dyslexia and superlexia should be equally prevalent. I've never heard of superlexia. Could it give rise to any problems?
What are the implications? There can be no doubt that some children underachieve as regards reading and need help. There may be a small hard core of children with stable dyslexia who need constant help but other children's reading achievement may fluctuate and they may need help at different times in their school careers. Reading disability, it seems, cannot be diagnosed once and for all in the early school years. 
